Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.
Not yet recruitingOBSERVATIONAL
Enrollment
125
Participants
Timeline
Start Date
December 31, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Conditions
Non-Hodgkin Lymphoma
Trial Locations (1)
40138
IRCCS Azienda Ospedaliero - Universitaria di Bologna, Bologna
All Listed Sponsors
lead
IRCCS Azienda Ospedaliero-Universitaria di Bologna
OTHER
NCT06720701 - Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma. | Biotech Hunter | Biotech Hunter